New drug shows promise for dialysis patients with hormone disorder
NCT ID NCT06747247
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called MT1013 in 98 adults on kidney dialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels are too high. The goal was to see if the drug is safe and can lower these hormone levels. Participants received either the drug or a placebo, and some took the drug long-term for up to 52 weeks. The study is complete, and results will show how well MT1013 controls the condition.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.